ICER to probe for clinical justification of drug price hikes

The Institute for Clinical and Economic Review unveiled more details on its plans to evaluate whether price increases for "high-impact" drugs are justified by new clinical evidence.

In a draft protocol published Thursday, ICER said it will rank the top 100 drugs by sales revenue, and from that select the top 10 drugs whose net price increase has had the largest impact on U.S. spending over the prior two years. ICER will consider adding up to three additional drugs based on public input...